Arnon, Tadmor-Levy represented BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, in the negotiation of a strategic collaboration agreement with GenFleet Therapeutics, an immuno – oncology focused biopharmaceutical company based in China, to advance BioLine’s leading candidate, Motixafortide, through a randomized Phase 2b clinical trial in pancreatic cancer.
The transaction, which involved complex cross-border and IP issues, is indicative of the potential for expanding collaboration between Israeli and Chinese partners in the field of life sciences. Daniel Green, Partner, and Leah Grumet, Associate, represented BioLineRx in the transaction.
